Follow @keithspeights
Recent articles
Should You Buy Pfizer in April?
For some investors, the answer is a resounding "yes."
3 Hot Healthcare Stocks Cathie Wood Is Buying in April
Here's why she likes them so much.
Why Bionano Genomics Stock Is Tumbling Today
No news; just run-of-the-mill volatility.
Here's Why Investors Liked UnitedHealth Group's Q1 Results
The health insurer delivered solid top- and bottom-line growth.
4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla
And they all have one key thing in common.
The Pot Stock Poised to Be the Biggest Winner With Virginia's Marijuana Legalization
But it might take a few years for it to happen.
3 Popular Robinhood Stocks That Warren Buffett Owns -- and You Should Too
They're great picks for any investor.
Why GlaxoSmithKline Stock Jumped Today
An activist investor is reportedly building a significant position in the drugmaker.
Why Dynavax Stock Jumped Today
Investors cheered good news from the company's COVID-19 vaccine partner.
How Soon Will Novavax File for Emergency Use Authorization for Its COVID Vaccine?
European filings will likely come sooner than the biotech's U.S. submission.
Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?
There's no need for alarm just yet.
3 Robinhood Stocks That Have More Than Doubled in 2021: Are They Buys Now?
These stocks are red-hot so far this year. But could they cool off in the coming months?
3 Dividend Stocks I'd Buy Right Now
Attractive dividend yields and solid businesses make these stocks stand out.
Why Ardelyx Stock Soared Today
The company's Japanese partner initiated pivotal late-stage studies of Ardelyx's lead candidate.
Why Amicus Therapeutics Stock Is Soaring Today
Investors cheered an analyst's upgrade of the biotech stock.
Why Novavax Stock Is Jumping Again Today
Investors appear to still think that bad news for Johnson & Johnson could be good news for Novavax.
Should AbbVie Be Worried About Rinvoq?
There's more reason to be concerned than in the past.
The Big Questions for Illumina After Its Q1 Sneak Peek and 2021 Guidance
The gene sequencing giant has a couple of key challenges going forward.
Why Are Participants in Novavax's COVID Vaccine Study Receiving 2 Extra Shots?
There's a simple -- and good -- reason.
Could Johnson & Johnson Be a Big Winner in the Flu Vaccine Market?
Maybe, but there's a long way to go.